Future perspectives: towards interferon-free regimens for HCV.

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection impacts 180 million globally, with a significant portion developing cirrhosis.
• HCV-related hepatocellular carcinoma and liver failure are projected to triple in the next 30 years.
• Current treatments like pegylated interferon (PEG-IFN) plus ribavirin (RBV) have limited efficacy and tolerability, especially for HCV genotype 1.

Purpose of the Study:

• To highlight the urgent need for novel, interferon-free, all-oral treatment regimens for HCV.
• To emphasize the requirement for direct-acting antiviral (DAA) drugs with diverse mechanisms of action and high resistance barriers.
• To improve cure rates across all HCV genotypes.

Main Methods:

• Review of current HCV antiviral therapies, including limitations of PEG-IFN/RBV and triple therapy.
• Analysis of the challenges posed by different HCV genotypes and patient subgroups.
• Discussion of the characteristics of an ideal future HCV treatment regimen.

Main Results:

• Existing therapies show suboptimal efficacy and tolerability, particularly for specific genotypes and patient populations.
• Triple therapies offer improvements but remain unsuitable for many patients due to contraindications or lack of response.
• A significant unmet need exists for effective, well-tolerated, all-oral DAA regimens.

Conclusions:

• An urgent need exists for interferon-free, all-oral direct-acting antiviral (DAA) regimens for Hepatitis C virus (HCV).
• Successful regimens will likely involve at least two DAAs with different targets and a high barrier to resistance.
• Treatment duration is expected to be 6-12 weeks, guided by virological response.